VIR Stock Analysis: Buy, Sell, or Hold?
VIR - Vir Biotechnology, Inc. Common Stock
$9.78
0.57 (6.19%)
▲
5d:
+5.84%
30d:
+4.71%
90d:
+8.31%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When VIR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: VIR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: VIR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: VIR is currently trading at $9.78, which is considered extended relative to its 30-day fair value range of $8.83 to $9.50.
Technical Outlook: Technically, VIR is in a downtrend. Immediate support is located at $8.77, while resistance sits at $10.08. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: VIR scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+114.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VIR is in a downtrend. Immediate support is located at $8.77, while resistance sits at $10.08. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: VIR scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+114.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.83 -
$9.50
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.2%)
- BULLISH: Trading 114.7% below Wall St target ($21.00)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.83 -
$9.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.77
Resistance Level
$10.08
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.92
Wall Street Target
$21.00
(+114.7%)
Revenue Growth (YoY)
19582.5%
Earnings Growth (YoY)
58.5%
Profit Margin
-83.0%
Share & Embed Analysis
Last updated: August 23, 2026 11:19 PM ET
Data refreshes hourly during market hours. Next update: 12:19 AM
Data refreshes hourly during market hours. Next update: 12:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VIR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Backer Marianne De
SELL
72559 shares
2026-04-06
Vicki L Sato
SELL
22000 shares
2026-04-01
Brent Sabatini
SELL
7711 shares
2026-03-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
